LDS/Medical Tests/5-Hydroxytryptamine Receptor 2C (HTR2C)

5-Hydroxytryptamine Receptor 2C (HTR2C)

5-Hydroxytryptamine Receptor 2C (HTR2C) is one of fourteen serotonin receptors that have been identified thus far. It is encoded by the HTR2C gene located at Xq23. The major function of HTR2c is the regulation of appetite, energy homeostasis, and mood. Abnormalities in the HTR2C may result in obesity and a number of psychiatric disorders. Since males only possess a single copy of the gene, any abnormality can affect them to a greater extent than in females.

Physiologically, the roles of HTR2C are accomplished within the serotonin system. Binding of the ligand to the transmembrane receptor brings conformational change, affecting the underlying G-protein to activate the Phospholipase C. Through a series of intermediate steps activation of this pathway results in controlled appetite and increased glucose uptake in tissues via enhanced insulin sensitivity. To the individual, it provides the sensation of fullness and satiety. For this reason, HTR2C has been a target of weight loss drugs. In contrast, HTR2C targeted antipsychotic drugs have been associated with uncontrolled obesity and cardiovascular co-morbidity.

Numerous single nucleotide polymorphisms including the 759C/T are identified that may alter the functionality and activity of HTR2C, inducing appetite, hyperphagia, and obesity. The presence of such SNPs may also result in decreased responses HTR2C agonists for weight loss. Investigating HTR2C abnormalities may be beneficial in treating obesity and psychiatric disorders in selected patients.

Genetic variation in the HTR2C gene in known to be partially involved in pathogenesis of some psychiatric disorders and adverse effects of antipsychotic medications. The HTR2C assay identifies mutations that are associated with altered serotonin receptor expression and function, which has important pharmacological and toxicological implications for the use of antipsychotic medications, such asolanzapine, clozapine and risperidone. Therefore, the HTR2C assay identifies mutations that lead to functional variability in serotonin receptor, which is associated with clinical response to antipsychotics. In particular, genotype of SNP rs3813929 is significantly associated with the side effect of weight gain in patients who are taking olanzapine for psychiatric disorders including schizophrenia. Patients who have the rs3813929 TT or CT genotype (female) or T genotype(male) may have a decreased risk of weight gain when compared to patients who have the rs3813929 CC genotype (female) or C genotype(male). Other genetic and clinical factors may also influence a patient's response to olanzapine. Genotype of SNP rs1414334 is significantly associated with the side effect of metabolic syndrome in patients taking clozapine or risperidone. Patients who have the rs1414334 GG genotype (female) or G genotype (male) may have a favorable response to clozapine or risperidone, and a decreased risk of developing metabolic syndrome when compared to patients who have the rs1414334 CC genotype (female) or C genotype(male). Other genetic and clinical factors may also influence a patient's response to clozapine and risperidone. In addition, HTR2C SNPs rs3813929 and rs1414334 may have other clinical implications in the treatment of psychiatric disorders such as depression, obsessive-compulsive disorder and anxiety-related conditions.

  • To evaluate response to antipsychotic medications, such as olanzapine, clozapine and risperidone
  • Aids in diagnosing the cause of uncontrolled obesity
  • Useful in investigating unresponsive treatment to HTR2C agonists for weight loss

SNP rs3813929 is significantly associated with the side effect of weight gain in patients who are taking olanzapine for psychiatric disorders including schizophrenia.

Patients who have the rs3813929 TT or CT genotype (female) or T genotype(male) may have a decreased risk of weight gain when compared to patients who have the rs3813929 CC genotype (female) or C genotype(male).

Other genetic and clinical factors may also influence a patient's response to olanzapine. SNP rs1414334 represents a C > G in the HTR2C gene is most significantly associated with a protective effect against the side effect of metabolic syndrome in patients taking clozapine or risperidone.

Negative for polymorphisms in the HTR2C gene

Real-time Polymerase Chain Reaction (PCR), Next-generation sequencing, massively parallel sequencing, sanger sequencing, sequencing of the entire coding region, deletion/duplication analysis.

Whole blood (preferred), Lavender-top (EDTA), buccal swab.

Stability whole blood

  • Ambient: 3-5 days
  • Refrigerated: 7-14 days
  • Frozen: 30 days

Buccal swabs

2 to 4 swabs in appropriate swab collection kits.

Swabs are stable in ambient temperature for up to 30 days.

Plasma serotonin level, serum cortisol, dopamine, prolactin, total calcium, vitamin D, plasma glucose, plasma ACTH, thyroid function test, CYP2D6, gene analysis for other serotonin receptors.
3-5 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login